Since the onset of the coronavirus disease 2019 (COVID-19) pandemic in early 2020, many individuals infected with the virus that […]
CADTH recommends that Velsipity be reimbursed by public drug plans for the treatment of adults with moderately to severely active
Canada is experiencing an important demographic transition toward an increasingly diverse aging population with an increased need for care and
Shared decision-making (SDM) in health care is a process in which both patients and providers are equal partners collaborating to
CADTH recommends that relugolix (Orgovyx) should be reimbursed by public drug plans for the treatment of advanced prostate cancer if
CADTH recommends that Apretude should be reimbursed by public drug plans for at-risk adults and adolescents aged 12 years and
Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) are 2 major chronic conditions that affect millions of Americans.
Registration No: 771800548 Contact Number : +91-8249516996
